Celgene acquired exclusive rights of BeiGene's PD-1 inhibitor BGB-A317, developed for non-hematological indications, and its commercial operations in China. BeiGene will receive $263 million in licensing fees and up to $980 million in milestones and royalties.
Celgene acquires rights to BeiGene's PD-1 inhibitor
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.